GH Research PLC
GHRS16.690USD
-2.810-14.41%
Cierre 07/22, 16:00（ET）Cotizaciones retrasadas 15 min
1.04BCap. mercado
PérdidaP/E TTM
Más Datos de GH Research PLC Compañía
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
Información de la empresa
Símbolo de cotizaciónGHRS
Nombre de la empresaGH Research PLC
Fecha de salida a bolsaJun 25, 2021
Fundada en2021
Director ejecutivoDr. Velichka (Villy) Valcheva, M.D.
Número de empleados50
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 25
DirecciónJoshua Dawson House
CiudadDUBLIN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísIreland
Código postalD02 RY95
Teléfono35314378334
Sitio Web
Símbolo de cotizaciónGHRS
Fecha de salida a bolsaJun 25, 2021
Fundada en2021
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Duncan Moore, Ph.D.
Dr. Duncan Moore, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Velichka (Villy) Valcheva, M.D.
Dr. Velichka (Villy) Valcheva, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Duncan Moore, Ph.D.
Dr. Duncan Moore, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Schonharting (Florian)
23.90%
BVF Partners L.P.
14.23%
RA Capital Management, LP
11.20%
Lynx1 Capital Advisors LLC
10.39%
Terwey (Theis)
9.98%
Other
30.31%
Accionistas
Accionistas
Proporción
Schonharting (Florian)
23.90%
BVF Partners L.P.
14.23%
RA Capital Management, LP
11.20%
Lynx1 Capital Advisors LLC
10.39%
Terwey (Theis)
9.98%
Other
30.31%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
33.88%
Hedge Fund
24.16%
Investment Advisor
18.53%
Venture Capital
12.14%
Investment Advisor/Hedge Fund
9.67%
Research Firm
4.41%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
81
63.75M
102.78%
+7.18M
2025Q1
80
63.74M
102.77%
+7.17M
2024Q4
74
51.85M
85.10%
-3.62M
2024Q3
76
51.78M
99.44%
-4.46M
2024Q2
78
51.68M
99.26%
-4.52M
2024Q1
77
50.90M
97.75%
-4.57M
2023Q4
73
50.91M
97.80%
-2.89M
2023Q3
74
50.54M
97.15%
-4.64M
2023Q2
82
51.15M
98.33%
-4.53M
2023Q1
76
51.21M
98.45%
-5.44M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Schonharting (Florian)
14.82M
23.9%
--
--
Dec 31, 2024
BVF Partners L.P.
8.83M
14.23%
-1.57M
-15.12%
Mar 31, 2025
RA Capital Management, LP
6.94M
11.2%
+257.96K
+3.86%
Mar 31, 2025
Lynx1 Capital Advisors LLC
6.44M
10.39%
+90.87K
+1.43%
Mar 31, 2025
Terwey (Theis)
6.19M
9.98%
--
--
Dec 31, 2024
RTW Investments L.P.
5.50M
8.87%
+2.17M
+65.30%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.25M
6.85%
+1.76M
+70.85%
Mar 31, 2025
Cormorant Asset Management, LP
2.01M
3.24%
+1.42M
+238.84%
Mar 31, 2025
Deep Track Capital LP
2.00M
3.22%
+2.00M
--
Mar 31, 2025
TD Securities, Inc.
1.97M
3.17%
+1.97M
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: dom., 6 de jul
Actualizado: dom., 6 de jul
Nombre
Proporción
AdvisorShares Psychedelics ETF
4.37%
iShares MSCI Ireland ETF
0.9%
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
SPDR S&P International Small Cap ETF
0.02%
ALPS Medical Breakthroughs ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
AdvisorShares Psychedelics ETF
Proporción4.37%
iShares MSCI Ireland ETF
Proporción0.9%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.89%
SPDR S&P International Small Cap ETF
Proporción0.02%
ALPS Medical Breakthroughs ETF
Proporción0%
Fidelity Nasdaq Composite Index ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
